Thymosin Alpha 1 is a clinically recognised immunomodulatory
peptide prescribed to support immune resilience and response.
Administered subcutaneously, it has been studied in clinical
immune modulation settings and is part of a supervised
treatment protocol.
Key Benefits:
– Supports and enhances immune response
– Supports immune resilience
– May improve infection response
– Used in clinical immune modulation
All therapies are prescribed following individual medical
assessment and administered under direct clinical supervision
in full accordance with DHA regulations.